Basal Tumours in Bladder Cancer, Response to chemoTherapy

Study Overview
=================
Brief Summary
-----------------
Determine the sensitivity/resistance to chemotherapy of the various subgroups of muscle-invasive bladder cancers, including the basal subgroup (about 25% of these tumours) according to 4 different classifications based on molecular or immunohistochemical classifiers.

Official Title
-----------------
Basal Tumours in Bladder Cancer, Response to chemoTherapy

Conditions
-----------------
Bladder Cancer, Chemotherapy Effect

Intervention / Treatment
-----------------
* Combination Product: neoadjuvant chemotherapy with cisplatine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria of Patients enrolled in VESPER study: Tumors from patient having muscle invasive bladder cancer who benefit from neoadjuvant chemotherapy with cisplatine included in VESPER cohort and : having signed an informed consent form for the participation to the collection or dead/lost to follow-up without prior opposition expressed against research program, genetic analysis will only be carried out for patients who have signed the genetic consent form. Inclusion Criteria of Patients from St Louis cohort not enrolled in VESPER study: Tumors from patient having muscle invasive bladder cancer who benefit from neoadjuvant chemotherapy with cisplatine included in Saint-Louis cohort and : having received an informed form for the participation to the collection and not having expressed opposition against research program within 1 month or dead/lost to follow-up without prior opposition expressed against research program, Exclusion Criteria: -Patients enrolled in VESPER study:Tumors from patient having withdrawn his/her informed consent form for the participation to the collection and/or VESPER project. OR -Patients from St Louis not enrolled in VESPER study:Tumors from patient having expressed opposition against research program after 1 month for the participation to the collection.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients enrolled in VESPER study<br>Tumors from patient having muscle invasive bladder cancer who benefit from neoadjuvant chemotherapy with cisplatine included in VESPER cohort | Combination Product: neoadjuvant chemotherapy with cisplatine<br>* Tumors from patient having muscle invasive bladder cancer who benefit from neoadjuvant chemotherapy with cisplatine<br>|
| Patients from St Louis cohort not enrolled in VESPER study<br>Tumors from patient having muscle invasive bladder cancer who benefit from neoadjuvant chemotherapy with cisplatine included in Saint-Louis cohort | Combination Product: neoadjuvant chemotherapy with cisplatine<br>* Tumors from patient having muscle invasive bladder cancer who benefit from neoadjuvant chemotherapy with cisplatine<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Identifying molecular subgroups of bladder cancer patients within VESPER and Saint-Louis cohort, who could benefit from neoadjuvant chemotherapy, taking into account the existence of different classification systems. |  | through study completion, an average of 3 years | 
| Determining which classification(s) has(ve) the best ability to identifying subgroups of tumours sensitive or resistant to neoadjuvant chemotherapy. |  | through study completion, an average of 3 years | 
| Identifying mechanisms of resistance in basal subgroups. |  | through study completion, an average of 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
neoadjuvant chemotherapy, cisplatine